US-based EverlyWell has raised $50m to continue to expand its range of at-home testing kits, which are used to diagnose a range of conditions. The company is also working on an app that will allow users to test their own blood for various conditions, including diabetes, high cholesterol and cancer. The company has grown from eight to 35 separate test kits since its launch in 2016. EverlyWell said the investment would primarily go towards brand building, while also being used to further develop the company's product range and retail footprint.
US-based EverlyWell has raised $50m to continue to expand its range of at-home testing kits, which are used to diagnose a range of conditions. The investment came from existing partners Goodwater Capital, NextGen Venture Partners and Next Coast Ventures, with support from new investor Highland Capital Partners. The company has grown from eight to 35 separate test kits since its launch in 2016. EverlyWell said the investment would primarily go towards brand building, while also being used to further develop the company's product range and retail footprint.